

1 An optimized pipeline for high-throughput bulk RNA-Seq deconvolution illustrates the impact of
2 obesity and weight loss on cell composition of human adipose tissue

3
4 Cheehoon Ahn¹, Adeline Divoux¹, Mingqi Zhou², Marcus M Seldin², Lauren M Sparks^{1*,#}, Katie L
5 Whytock^{1*}

6 ¹Translational Research Institute, AdventHealth, Orlando, FL, USA

7 ²Department of Biological Chemistry and Center for Epigenetics and Metabolism, University of
8 California, Irvine, Irvine, CA, USA

9 *Co-corresponding author

10 #Senior author

11

12

13 **SUMMARY**

14 Cellular heterogeneity of human adipose tissue, is linked to the pathophysiology of obesity and
15 may impact the response to energy restriction and changes in fat mass. Here, we provide an
16 optimized pipeline to estimate cellular composition in human abdominal subcutaneous adipose
17 tissue (ASAT) from publicly available bulk RNA-Seq using signature profiles from our previously
18 published full-length single nuclei (sn)RNA-Seq of the same depot. Individuals with obesity had
19 greater proportions of macrophages and lower proportions of adipocyte sub-populations and
20 vascular cells compared with lean individuals. Two months of diet-induced weight loss (DIWL)
21 increased the estimated proportions of macrophages; however, two years of DIWL reduced the
22 estimated proportions of macrophages, thereby suggesting a bi-phasic nature of cellular
23 remodeling of ASAT during weight loss. Our optimized high-throughput pipeline facilitates the
24 assessment of composition changes of highly characterized cell types in large numbers of ASAT
25 samples using low-cost bulk RNA-Seq. Our data reveal novel changes in cellular heterogeneity
26 and its association with cardiometabolic health in humans with obesity and following weight loss.

27

28 Lead contact: Katie Whytock (Katie.Whytock@adventhealth.com)

29 **INTRODUCTION**

30 Adipose tissue is an important lipid storage and endocrine organ (1-3) that is highly
31 heterogeneous where non-adipocytes compose more than 50% of the total cell population and
32 reside within the stromal vascular fraction (e.g. stem cells, pre-adipocytes, vascular cells, and
33 immune cells) (4, 5). While excess adiposity is associated with cardiometabolic disease
34 progression (6, 7), increasing evidence suggests that altered cellular composition of adipose
35 tissue – and not the sheer mass *per se* – is also tightly linked to, or even at the root of,
36 cardiometabolic health complications that are often observed with obesity (8-10). Conversely,
37 improvements in cardiometabolic health induced by weight loss are often accompanied by
38 changes in the cellular composition of adipose tissue, particularly macrophages (11, 12).
39 However, a comprehensive analysis of cell types that may be altered by weight loss is still
40 lacking. Therefore, robust and accurate quantification of cell proportions in adipose tissue is
41 paramount for understanding the etiology of cardiometabolic disease and optimizing its
42 treatment.

43
44 Since the advent of transcriptomics, researchers have sought to deconvolute bulk transcriptomics
45 to estimate cell type proportions. This approach has surged with the development of single cell
46 (sc) and single nuclei (sn) RNA-Seq platforms that can more accurately quantify cellular
47 composition and provide cell-specific transcriptomes to aid in bulk deconvolution. While sc/sn
48 RNA-Seq remains the most accurate way to quantify cell composition in adipose tissue with
49 minimal bias, the pipeline remains expensive and requires technical bench-work that restricts
50 broad application. Recently, we published a full-length snRNA-Seq atlas of abdominal
51 subcutaneous adipose tissue (ASAT) from a prospective cohort of older and younger adults
52 balanced for sex and body mass index (BMI) (13). The full-length snRNA-Seq methodology
53 provided the highest gene detection per nuclei in human adipose tissue to date, therefore
54 providing an exemplary dataset for accurate bulk RNA-Seq deconvolution. While bulk RNA-Seq
55 deconvolution using sc/snRNA-Seq profiles has previously been performed in human ASAT (9,
56 14, 15), to date no one has systematically identified which algorithm and signature matrix yields
57 the most accurate results.

58
59 Here, we leverage our full-length snRNA-Seq human ASAT dataset to optimize a pipeline to
60 deconvolute bulk RNA-Seq datasets and determine how cellular heterogeneity of ASAT may be
61 altered with both obesity and weight loss. Understanding the impact of one of the most cost-
62 effective and commonly prescribed interventions to treat obesity-related cardiometabolic health
63 complications may lead to advanced weight loss strategies and cellular targets for improving
64 cardiometabolic health outcomes.

65 66 **RESULTS**

67 **Assessment of deconvolution algorithms**

68 Given there are currently several popular deconvolution algorithms, we aimed to assess which
69 algorithm had the ability to 1) detect every cell type that we previously reported (13), from a large
70 bulk RNA-Seq data set and 2) how accurately we could deconvolute a pseudobulk RNA-Seq data
71 set, which is a bulk-like profile where gene expression data from individual nuclei are aggregated
72 for each sample with known cell type proportions. In our preliminary testing, we compared popular

73 algorithms for their capability of detecting each cell type in the majority of samples from a large
74 bulk RNA-Seq data set (METabolic Syndrome In Men; METSIM cohort (16) **Figure 1**). We also
75 reasoned that for the algorithm to be effective it should be able to detect at least 25% of adipocytes
76 in the majority of these samples (17). The results show that certain algorithms, despite the
77 different gene composition iterations, were never reliable in detecting certain cell types. For
78 example, when using all detected genes ('All Genes') and top 5000 highly variable genes (HVG)
79 – which were used to cluster cell types in the original snRNAseq data (13) – rls and qprogwc
80 always underestimated vascular cells. nnls (operated through ADAPTS or granulator) did not
81 identify adipocytes in a large portion of samples (**Figure 1A, S1A**). MuSiC- weighted consistently
82 underpredicted stem and vascular proportions whereas MuSiC – all gene underpredicted
83 macrophages and pre-adipocyte proportions (**Figure 1A, S1A**). While EPIC was able to detect all
84 cell types, the proportion of these certain cell types in samples was extremely low (<1%) and
85 therefore was not a completely reliable detection. Some algorithms such as ols, qprog, DCQ,
86 proportionsInAdmixture, and DeconRNASeq were able to detect adipocytes in a large proportion
87 of samples. However, these adipocyte estimates had an extremely low proportion of samples that
88 had >25% of adipocyte estimated (**Figure 1B**). It was notable that dtangle was able to detect all
89 cell type in every sample when all genes or 5000HVG signature was used (**Figure 1A, S1A**).
90 Furthermore, dtangle consistently detected at least 25% of adipocytes in nearly 100% of samples
91 (**Figure 1B, S1B**).

92
93 In order to assess the effectiveness of different deconvolution algorithms, we compared estimated
94 cell proportions from a pseudobulk data-set against actual cell-type proportions quantified with
95 snRNA-Seq. Pearson's correlation coefficient (-1 to 1) and mean absolute deviance (mAD) (0-
96 100) were used to assess how accurately the deconvolution estimated cell type proportions, with
97 a PCC of 1 and mAD of 0 indicating a completely accurate prediction of a given cell type (**Figure**
98 **1C-F**). Overall dtangle, rls and MuSiC-weighted had the highest PCC values (**Figure 1C-D**).
99 dtangle and MuSiC-weighted had the lowest average mAD out of all the algorithms that were able
100 to detect every cell type (**Figure 1E-F**).

101 102 **Signature Matrix Optimization**

103 Due to dtangle being the best-performing algorithm from the bulk and pseudobulk RNA-Seq
104 deconvolution assessments, we further sought to optimize this specific algorithm.

105
106 In adipose tissue biology, macrophage content increases proportionally to increases in adipose
107 tissue mass (18). We therefore reasoned that when deconvoluting bulk RNA-Seq data, we should
108 see a positive correlation between macrophage proportion and adiposity (i.e., BMI and waist-to-
109 hip ratio (WHR)). We ran different iterations of gene signatures to assess which gave us the best
110 correlation between macrophage proportion and BMI or WHR. We tested; all genes detected, and
111 different iterations of HVG (2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000). Every gene
112 signature was able to detect every cell type in every sample (**Figure 2A**). However, 'All genes'
113 *signature matrix* predicted similar proportions of macrophages across all samples and therefore
114 there was no correlation between percentage of macrophage proportion and WHR (**Figure 2B,**
115 **D**) or BMI (**Figure S2A**). This highlights the need to optimize a gene signature when performing
116 deconvolution rather than using all of the genes available. The 6000 HVG had the highest

117 correlation between both WHR and BMI with estimated proportion of macrophages, although
118 5000 HVG, 4000 HVG, and 3000 HVG elicited similar results (**Figure 2B, C, S2A**).

119
120 We further explored whether the snRNAseq-derived gene signature matrix and 6000 HVG list
121 were influenced by the age of the participants as our snRNAseq reference data comprises
122 samples from 10 older (≥ 65 years) and 10 younger (≤ 30 years) participants (13). By applying
123 age-group specific gene signature matrices and age-group specific 6000 HVG lists to deconvolute
124 METSIM bulk RNA-seq data, we found that macrophages were overestimated while pre-
125 adipocytes were underestimated when using gene signature matrix and 6000 HVG list from
126 younger adults compared with when using those from older adults (**Figure S2B-C**). In addition to
127 our main signature matrix and 6000 HVG from the age-group-integrated data, we provide age-
128 group-specific data (**Supporting information**). Using the 6000 HVG from the two different age
129 groups, we found that 4762 genes among 6000 HVG (65.9%) were shared by both groups,
130 suggesting that these 4762 genes may represent ‘age-neutral’ genes (**Figure S2D**). There was a
131 remarkably tight correlation between the estimated proportions of each cell type from METSIM
132 bulk RNA-seq data using the age-group-integrated 6000 HVG and ‘age-neutral’ 4762 HVG (0.94
133 $< R < 0.99$) (**Figure S2E**), indicating that the initial 6000 HVG we tested may robustly estimate
134 ASAT cell type proportions with minimal bias by age.

135

136 **Deconvolution reveals distinct ASAT heterogeneity in obesity**

137 To further examine how ASAT cellular heterogeneity may be implicated in obesity and
138 cardiometabolic health, we deconvoluted ASAT bulk RNA-seq data from previously published
139 reports that collected ASAT from cohorts of lean and individuals with obesity that represented a
140 wide range of age; adolescents (<18 years; obesity defined as 97th percentile BMI; “LCAT cohort”)
141 (**Figure 3A**) (19), young and middle-aged adults (18-55 years; “Petersen et al., 2024”) (**Figure**
142 **3B**) (20), and older adults (55-70years; “MD lipolysis cohorts”) (**Figure 3C**) (21). In addition to
143 cohorts of adults with obesity who had relatively healthier cardiometabolic health traits (i.e.
144 Metabolically Healthy Obese, MHO and Obese with insulin resistance, Obese-IR), two studies
145 had another cohort that had impaired cardiometabolic health traits. For example, Metabolically
146 Unhealthy Obese (MUO) had prediabetes, hepatic steatosis, and whole-body insulin resistance
147 (**Figure 3B**) and Obese with Type 2 diabetes (Obese-T2D) were recently diagnosed with T2D by
148 the time they were recruited (**Figure 3C**). Importantly, these cohorts were matched to their
149 healthier cohorts with obesity by sex, age, and adiposity (see more details in ‘*Human studies and*
150 *deconvolution analysis*’). Consistently observed across different age groups, our deconvolution
151 analysis estimated a higher proportion of macrophages and a lower proportion of vascular cells
152 in individuals with obesity compared with lean cohorts, aligning with the adipose tissue
153 abnormalities (i.e., macrophage infiltration and capillary rarefaction) commonly observed in
154 obesity (18, 22, 23) (**Figures 3A-C**). We previously characterized two adipocyte populations using
155 snRNA-Seq (13). Adipocyte 1 was characterized by an upregulation of genes related to anti-
156 oxidation (*GPX1* & *GPX4*) and pathways related to complement, oxidative phosphorylation and
157 Srp dependent translational protein targeting to membrane and was labeled as ‘anti-oxidative’,
158 while adipocyte 2 was labeled as ‘insulin-responsive’ adipocyte, demonstrated by upregulation of
159 genes related to suppression of lipolysis (*PDE3B*), lipid metabolism (*ABCA5*), and of pathways

160 related to insulin receptor signaling cascade (13). Interestingly, the estimated proportions of both
161 adipocytes were also lower in individuals with obesity compared with lean individuals (**Figures**
162 **3A-C**). The estimated proportions of pre-adipocytes, stem cells, and mast cells were comparable
163 between the individuals with obesity compared with lean (**Figures 3A-C**).

164 165 **Deconvolution reveals ASAT cell types that are linked with poor cardiometabolic health**

166 Macrophage infiltration and capillary rarefaction in ASAT are often associated with unfavorable
167 cardiometabolic health in obesity, but the interpretation of their direct link can be confounded by
168 increasing ASAT mass (7, 24). We investigated whether the estimated cellular composition differs
169 between adults with obesity who have cardiometabolic health complications (i.e., MUO and
170 Obese-T2D) and those well-matched individuals with obesity who are relatively healthy (i.e., MHO
171 and Obese-IR). Compared with the MHO group, the MUO group was estimated to have a higher
172 proportion of macrophages ($p=0.0001$) and a lower estimated proportion of adipocyte 2 and
173 vascular cells ($p=0.02$ and $p=0.0008$, respectively) (**Figure 3B**). In the MD lipolysis cohorts, while
174 the estimated proportion of adipocyte 2 was not different between older lean vs. older adults with
175 Obese-IR, it was significantly lower in older adults with Obese T2D when compared with lean
176 ($p=0.0008$) (**Figure 3C**). There was a trend for lower estimated proportion of vascular cells in
177 Obese T2D compared to lean ($p=0.07$) (**Figure 3C**), collectively suggesting that alterations in
178 macrophage and vascular cell populations may be directly linked with impairments in
179 cardiometabolic health. Intriguingly, our findings further suggest that a lower proportion of insulin-
180 responsive adipocytes may also be implicated in adverse cardiometabolic health outcomes.

181 We then used a 'gene inference' approach to understand whether or how specific phenotypes of
182 adipose tissue macrophages (e.g., M1-like pro-inflammatory vs. M2-like anti-inflammatory) may
183 be altered with obesity. By using marker genes for M1-like lipid-associated macrophage (LAM)
184 ($n=317$ genes) or M2-like resident macrophages ($n=2724$ genes) that we previously acquired from
185 our parent snRNA-Seq data (13), we conducted a correlation analysis between marker gene
186 expressions and estimated proportions of macrophages. The number of resident macrophage
187 marker genes that are significantly and positively correlated with the estimated proportion of
188 macrophages was lower in adults with obesity (i.e., MHO and Obese IR) compared to lean (**Figure**
189 **3D**), and higher in adolescents with obesity compared with lean adolescents (**Figure 3D**). These
190 data suggest a possibility that adipose tissue macrophage polarization may be differentially
191 regulated with obesity in youth. Notably, the number of associated marker genes for LAM was
192 higher in adults with obesity and impaired cardiometabolic health (i.e., MUO and Obese T2D)
193 compared with their well-matched obese groups (**Figure 3D**), aligning with the authors' finding of
194 higher markers of whole-body and local inflammation in MUO and Obese T2D (20, 21).

195 196 **Diet-induced weight loss modifies ASAT cell type proportions**

197 Diet-induced weight loss (DIWL) is known to improve cardiometabolic health, often accompanying
198 alterations in the ASAT microenvironment that include reduced inflammation and improved lipid
199 metabolism (25-28). However, it is unclear whether cell type composition in ASAT can be modified
200 by DIWL and may underlie the improved health outcomes observed with DIWL. We deconvoluted
201 ASAT bulk RNA-Seq data from several dietary intervention studies that induced weight loss of
202 ~10% (range: 8~11%). Comprehensive Assessment of the Long-term Effects of Reducing Energy

203 Intake (CALERIE) Study is a randomized clinical trial that examined the effects of 12 and 24
204 months of 25% caloric restriction (CR) in humans without obesity (29). Compared with the control
205 group (AL, Ad Libitum), participants in the CR group lost ~11% of weight (~6kg fat mass) in
206 response to 12 months of CR, which was maintained at 24 months (**Table S1**). Our deconvolution
207 analysis suggested that the proportion of macrophages was significantly reduced after 12 and 24
208 months of CR compared to baseline ($p=0.002$ and $p=0.003$, respectively) (**Figure 4A**). In
209 concordance with this finding, there was a trend of positive correlation between the change in fat
210 mass (Δ kg) and the change in estimated macrophage proportion (Δ %) from baseline to month
211 12 ($p=0.07$) (**Figure 4B**) i.e. a decrease in fat mass (kg) correlates with decreases in estimated
212 macrophage proportion. Interestingly, we did not observe a decrease in estimated macrophage
213 proportion in the other two studies where short-term caloric restriction was prescribed to
214 individuals with overweight/obesity. In the Diet, Obesity, and Genes (DiOGene) study, 220 adults
215 with overweight/obesity (Age: 18-65 years, BMI: 27-45kg/m²) underwent an 8-week low-calorie
216 diet (LCD), all achieving at least 8% weight loss by the time of their post-ASAT sample collection
217 (**Table S2**) (26). In agreement with the findings of upregulated expression of macrophage genes
218 in these participants (26), our deconvolution analysis suggested an increased proportion of
219 macrophages in response to eight weeks of LCD ($p=5.64e-13$) (**Figure 4C**). Conversely, the
220 estimated proportion of adipocyte 1, adipocyte 2, and vascular cells was reduced ($p=2.24e-17$,
221 $8.32e-5$, 0.016 , respectively) with a slight increase in estimated stem cell proportion ($p=0.014$)
222 (**Figure 4C**). Similarly, we observed a trend of increased estimated proportion of macrophages
223 ($p=0.062$) and reduced estimated proportion of adipocyte 1 and adipocyte 2 ($p=0.021$ and 0.013 ,
224 respectively) from a small cohort of women with obesity ($n=10$, Age: 61 ± 4 years, BMI: 39 ± 3 kg/m²)
225 who rapidly lost ~10% of their weight through very low-calorie diet (VLCD) over 6.6 ± 2.2 weeks
226 (**Figure 4D, Table S2**) (27). Interestingly, the authors of this study reported an increased density
227 of crown-like structures – which are aggregates of macrophages – in ASAT after VLCD, which
228 aligns with our findings from the deconvolution analysis.

229 Additionally, the number of significantly associated marker genes for both LAM and resident
230 macrophages with estimated proportions of macrophages was reduced by 12 and 24 months of
231 CR in CALERIE (**Figure 4E**). However, the magnitude of reduction was greater in LAM marker
232 genes compared with resident macrophage marker genes, leaving less than 10% of significantly
233 associated genes after 2 years of CR (**Figure 4E**). Although we observed an increased estimated
234 proportion of macrophages in DioGenes cohorts and Aleman et al., 2017 (**Figures 4C, D**), our
235 ‘gene inference’ approach showed a greater increase in the number of resident macrophage
236 marker genes that are associated with estimated macrophage proportion, compared with LAM
237 marker genes. This finding suggests that the increased estimated proportion of macrophages by
238 short-term DIWL in adults with obesity may have been driven by an increased abundance of
239 resident macrophages, which has been reported to buffer lipids and counteract inflammatory
240 responses, thereby contributing to appropriate and favorable adipose tissue remodeling (30).

241

242

243 **DISCUSSION**

244

245 Using publicly available algorithms and a refined the reference data derived from our published
246 full-length snRNA-Seq (i.e., gene signature matrix and 6000HVG (13)), we established a

247 deconvolution pipeline that robustly estimates ASAT cell type proportions from bulk RNA-Seq
248 data that requires less cost and labor compared with sc or snRNA-seq. Using this algorithm, we
249 identify cellular heterogeneity in obesity, which is characterized by higher proportions of
250 macrophages, and lower proportions of adipocytes and vascular cells. Additionally, altered
251 abundance of some cell types, such as insulin-responsive adipocytes, macrophages, and
252 vascular cells may directly underlie the impaired cardiometabolic health in individuals with obesity.
253 We further show a dynamic change in cell type proportions in response to DIWL, which may play
254 an important role in mediating some of the health benefits conferred by DIWL.

255
256 Increased adipose tissue macrophage infiltration and capillary rarefaction are hallmarks of
257 excessive adiposity that are tightly associated with functional abnormalities in adipose tissue (8,
258 22, 23, 31). Our findings of higher estimated proportions of macrophages and lower estimated
259 proportions of vascular cells in individuals with obesity confirm this notion and further suggest that
260 these ASAT abnormalities are linked with cardiometabolic health complications independent of
261 ASAT mass. Additionally, higher estimated proportions of macrophages in MUO and Obese-T2D
262 were associated with more marker genes of LAMs compared with MHO and Obese-IR
263 respectively, suggesting that alterations in both macrophage abundance and phenotype may be
264 directly linked with cardiometabolic health complications in middle-aged and older adults.
265 However, this phenotypical switch of macrophages towards a pro-inflammatory type during the
266 progression of obesity may not apply in adolescent populations. We found that the estimated
267 proportions of macrophages in adolescents with obesity in the LCAT cohorts were more
268 associated with marker genes for anti-inflammatory type resident macrophages. We speculate
269 that ASAT in adolescents with obesity may require a higher abundance of resident macrophages
270 because it is under continuous tissue expansion and remodeling at such a young age (32-34).

271
272 Our deconvolution outcomes suggested a possibility of a lower proportion of mature adipocytes
273 in obesity, which serve as primary storage for excess lipid. Lower proportions of adipocytes do
274 not translate to lower number of total adipocytes when comparing individuals with obesity to lean
275 individuals. For example, the total number of adipocytes was estimated to be more than 2.5-fold
276 higher in adolescents with obesity compared to lean adolescents in the LCAT cohorts (35).
277 Therefore, while total adipocytes in adipose tissue may be increased with increasing adiposity, its
278 relative abundance to other cell types appears to be reduced. Our novel finding that the estimated
279 proportion of insulin-responsive adipocytes (adipocyte 2), characterized by upregulated genes
280 involved in lipid storage/metabolism and insulin signaling (13), was lower in individuals with
281 obesity and impaired cardiometabolic health (i.e., MUO and Obese-T2D) compared with matched
282 individuals with obesity who are relatively healthy (i.e., MHO and Obese-IR) indicates a tight
283 relationship between adipocyte heterogeneity and cardiometabolic health. Although the potential
284 mechanistic link bridging these two is unclear, the lower estimated proportion of adipocyte 2 in
285 MUO was paralleled with significantly higher ectopic fat mass (i.e., intra-abdominal adipose tissue
286 and intrahepatic triglyceride content) (20), which is indicative of impaired lipid storage capacity of
287 the ASAT (36, 37). We therefore speculate that the lower abundance of adipocyte 2 may have
288 contributed to the limited lipid storage capacity of ASAT in MUO, resulting in the accumulation of
289 ectopic fat, which can cause tissue-specific and whole-body insulin resistance (38).

290

291 Although DIWL-mediated attenuation of systemic inflammation has been commonly reported in
292 individuals with overweight/obesity (39, 40), the CALERIE study was the first to reveal that
293 reduced markers of systemic inflammation after one to two years of CR in individuals without
294 obesity (41). We found a reduced estimated proportion of ASAT macrophages after one and two
295 years of CR in the CALERIE cohort which may explain the reduced systemic inflammation.
296 Reduced proportions of macrophages by one and two years of CR was also paralleled by a vast
297 reduction of the number of associated marker genes for LAM, suggesting a phenotypical switch
298 of macrophages in addition to the change of abundance. Conversely, the increased estimated
299 proportion of ASAT macrophages in response to DIWL from DioGenes cohorts and participants
300 in Aleman et al (27) indicates that cellular remodeling during DIWL may vary significantly
301 depending on specific conditions and contexts. These findings support the ‘biphasic’ responses
302 in adipose tissue inflammation during weight loss, where markers of macrophages and
303 inflammation are increased during early weight loss then followed by a larger reduction as
304 weight loss sustains (11, 25, 42). Perhaps, our view is that weight loss may improve lipolytic
305 capacity of adipocytes that in turn induces macrophage recruitment (11), and our gene
306 inference data suggest that this rise may be driven by an increased abundance of M2-like
307 resident macrophages, indicating a potentially favorable adaptation (43).

308 Weight loss induces extensive morphological and functional remodeling of adipocytes, which
309 includes reduced adipocyte size and restoration of lipid metabolism in obesity (11, 25, 44). Our
310 finding of a reduced estimated proportion of adipocytes after short-term DIWL in adults with
311 obesity (DioGenes and Aleman et al.) suggests a potential modification in adipocyte
312 ‘abundance’ by weight loss. While this may simply be a reciprocal shift in proportion due to an
313 increased proportion of other cell types (e.g., macrophage and stem cell), we cannot rule out the
314 possibility that this may reflect changes in adipocyte turnover (i.e., net balance between
315 adipocyte formation and deletion). Weight loss may inhibit adipogenesis (45) which may
316 contribute to the negative balance of adipocyte abundance. However, many studies suggest the
317 opposite (46, 47), and it is unlikely that the reduced rate of adipogenesis was translated into a
318 meaningful reduction in adipocyte abundance in a relatively short period (~8 weeks) given the
319 slow rate of adipogenesis in humans (34). Alternatively, increased adipocyte apoptosis may
320 have driven cellular turnover during weight loss (48). Interestingly, it was previously
321 demonstrated that removal of adipocytes by apoptosis recruited M2-like macrophages into
322 adipose tissue in mice (49), which may also explain the increased association of resident
323 macrophage marker genes with increased estimated proportion of macrophages in response to
324 short-term DIWL.

325 Although our study enabled robust estimation of cell type proportions in human ASAT from bulk
326 RNA-Seq data, it is important to acknowledge some limitations that are inherent to *in silico*
327 analysis. Since the bulk RNA-Seq datasets we used were derived from other authors, we could
328 not directly validate our deconvolution analysis with the original tissue samples. However, many
329 of our cell type estimations align with findings from original articles. For example, our findings of
330 higher macrophage proportion in adolescents with obesity and after short-term VLCD in adults
331 with obesity parallel with the higher macrophage immunostaining in LCAT cohorts with obesity
332 and increased CLS after rapid VLCD in adults with obesity from Aleman et al. respectively,
333 supporting the robustness and accuracy of our deconvolution pipeline. Additionally, while the

334 full-length snRNA-Seq data from which we generated reference data has a superior gene
335 coverage rate per nuclei compared with conventional single-end (i.e., 3'-end) snRNA-Seq
336 techniques, subtypes of macrophages were not defined at the parent level, preventing direct
337 estimation of those cell populations. However, by associating marker genes of LAM and
338 resident macrophage acquired from a secondary cell clustering analysis (13) with estimated
339 proportion of macrophages, we show that macrophage phenotypes may be altered by obesity
340 and DIWL. Furthermore, the intriguing findings that the abundance of certain cell types (i.e.,
341 adipocyte 2, macrophage, and vascular cell) may be associated with the progression of
342 cardiometabolic health complications, yet the direct linkage remains inconclusive.

343 In summary, our findings indicate that compared with lean individuals, those with obesity exhibit
344 distinct cellular heterogeneity in ASAT, and further alterations in cell type proportions are tightly
345 linked with impaired cardiometabolic health. Moreover, DIWL can induce dynamic alterations in
346 ASAT cell type proportions, potentially contributing to the improved cardiometabolic health.
347 Overall, our work expands the understanding of adipose tissue cellular heterogeneity implicated
348 in cardiometabolic health and weight loss interventions by providing an optimized computational
349 deconvolution pipeline that can be easily used to estimate cell type proportions in human ASAT.

350

351

352

353 **METHODS**

354

355 **BIOINFORMATIC ANALYSES**

356

357 **DATA GENERATION**

358 Source data was generated in Seurat V4.4.0 with SeuratObject V4.1.4 using a previously
359 published data set (13). Seurat objects from each individual sample were merged into 1 large
360 seurat object before being split into a list of seurat objects based on individual samples.
361 SCTtransform with glmGamPoi was performed on this seurat list. Highly Variable Genes (HVG)
362 were determined by performing SelectIntegrationFeatures() on the SCTtransformed seurat list.

363

364 A signature matrix was generated using AggregateExpression() and aggregating
365 SCTtransformed counts for each cell type across all participants. The signature matrix was then
366 filtered by HVG list and used for subsequent deconvolution analyses. A pseudobulk RNA-Seq
367 data set was generated by using AggregateExpression() and aggregating SCTtransformed
368 counts for each sample across all cell types.

369

370 **PIPELINE OPTIMIZATION**

371 We initially compared popular deconvolution algorithms that were either operated through R
372 package granulator (50) (ols- ordinary least squares, qprog – quadratic programming without
373 constraints, rls- re-weighted least squares (51), qprogwc- quadratic programming with non-
374 negativity and sum-to-one constraint (52), nnls- non negative least squares (53) and dtangle (54))
375 or R package ADAPTS (55) (DCQ- Digital cell quantifier (56), deconRNASeq (52), nnls- non
376 negative least squares and ProportionsInAMixutre) and from stand alone R Packages MuSiC

377 (weighted and All Genes) (57) and EPIC (58). As nnls algorithm was included in both granulator
378 and ADAPTS we used both and assigned an A for Adapts and G for Granulator to identify which
379 package it was performed on.

380

381 *Algorithms comparison*

382 We tested each algorithms capability of detecting each cell type and detecting at least 25% of
383 adipocytes in the majority of samples from a large bulk RNA-Seq data set (METabolic Syndrome
384 In Men; METSIM cohort, GSE135134 (16)). To ensure we were not prematurely dismissive of a
385 certain algorithm we tested the deconvolution using; the full gene signature (**Figure S1A, B**), and
386 using a signature matrix that used 5000 highly variable genes (named 5000 HVG) that was used
387 for clustering in the original snRNA-Seq analyses. We reasoned that these 5000 HVG dictated
388 the clustering of cells and therefore would be an optimal initial signature to detect cell types in
389 bulk RNA-Seq data. For deconvolution using algorithms from granulator, function deconvolute()
390 was performed with the TPM-normalized bulk RNA-Seq data and the SCTransform signature
391 matrices. For deconvolution using algorithms using ADAPTS, functions estCellPercent.nnls(),
392 estCellPercent.DCQ(), est.CellPercent.proportionsInAMixture(), estCellPercentDeconRNASeq()
393 were performed with the TPM-normalized bulk RNA-Seq data and the SCTransform signature
394 matrices. For deconvolution using MuSiC the integrated Seurat Object was first converted to a
395 SingleCellExperiment with function as.SingleCellExperiment(). The TPM-normalized bulk RNA-
396 Seq data was converted to an expression matrix with ExpressionSet() and exprs() and then
397 music_prop() was performed with either all genes or with markers argument set to the 5000 HVG.
398 For deconvolution using EPIC function EPIC() was performed on the TPM normalized bulk RNA-
399 Seq data and the SCTransform signature matrices. For each cell type the percentage of samples
400 estimated to have that cell type was calculated, in addition to the percentage of samples estimated
401 to have at least 25% of adipocytes (adipocyte_1 and adipocyte_2 combined).

402

403 *Pseudobulk assessment*

404 In order to assess the effectiveness of different deconvolution algorithms we compared estimated
405 cell proportions from a pseudobulk data-set against actual cell-type proportions quantified with
406 snRNA-Seq. In this instance deconvolution was performed with the above functions and with the
407 5000HVG signature matrix but instead with a pseudobulk RNA-Seq data that was generated from
408 aggregated SCTtransformed counts for each sample across all cell types. Principle correlation
409 coefficient (-1 to 1) and mean absolute deviance (mAD) (0-100) were used to assess how
410 accurately the deconvolution estimated cell type proportions. MAD was calculated as the sum of
411 the absolute differences between the predicted proportion from the actual proportion divided by
412 the by the total number of samples (n = 20).

413

414 *Signature Matrix Optimization*

415 Using the SelectIntegrationFeatures() we generated iterations of HVG lists (2000, 3000, 4000,
416 5000, 6000, 7000, 8000, 9000, 10000) and filtered the signature matrix to these gene lists creating
417 a list of signatures matrices. Deconvolution was then performed using deconvolute() with just
418 dtangle algorithm, using the list of signature matrices and the TPM normalized bulk RNA-Seq
419 METSim data. Estimated Macrophage proportions were correlated to BMI and WHR (59), using

420 function bicorAndPvalue() from R Package WGCNA (60), to determine which signature matrix
421 elicited the most meaningful known physiological results.

422

423 *Macrophage subtype marker gene inference*

424 Marker genes for LAM (n=317) and resident macrophages (n=2724) were acquired by using
425 FindMarker() function in *Seurat* (logFC>0.5, adjusted p<0.05) from sub-clustered macrophages
426 (13). Significantly correlated marker genes of LAM or resident macrophages with estimated
427 proportion of macrophages from each publicly available dataset were acquired by using
428 bicorAndPvalue() from R Package WGCNA (60) (p<0.05).

429

430

431 **HUMAN STUDIES AND DECONVOLUTION ANALYSIS**

432

433 *Leipzig Childhood Adipose Tissue (LCAT) cohorts.* The LCAT cohort includes white children, both
434 female and male, aged 0-18 years who underwent elective orthopedic surgeries,
435 herniotomy/orchidopexy, or other surgical procedures (35). Youth participants with severe
436 diseases and medications that could influence adipose tissue biology, such as diabetes,
437 generalized inflammation, malignant diseases, genetic syndromes, or permanent immobilization,
438 were excluded. Obesity was defined by cutoffs of 1.88 standard deviation score, corresponding
439 to the 97th percentile. During surgery, subcutaneous adipose tissue samples were collected,
440 washed three times in PBS, and immediately frozen in liquid nitrogen for RNA extraction. RNA
441 sequencing was completed on 35 normal weight participants (13 female and 22 male) and 26
442 participants with obesity (14 female and 12 male) as described previously (61). Gene count matrix
443 was acquired from GSE141221, and subsequently normalized using DESeq2.

444

445 *Metabolically healthy lean (MHL), healthy obese (MHO), and unhealthy obese (MUO) cohorts.*

446 The study cohort includes 55 females and males, aged 18-55 years who were classified into three
447 groups based on cardiometabolic health criteria (20). MHL (n = 15; 7 males and 8 females) was
448 defined as having a body mass index (BMI) of 18.5–24.9 kg/m², and normal fasting plasma
449 glucose (<100 mg/dL), oral glucose tolerance (2-h glucose <140 mg/dL), IHTG content (≤5%),
450 plasma triglycerides (<150 mg/dL), and normal whole-body insulin sensitivity, defined as the
451 glucose infusion rate (GIR) per kg fat-free mass divided by the plasma insulin concentration
452 (GIR/I) during the final 20 min of the HECP >40 (μg/kg FFM/min)/(μU/mL). MHO (n = 20; 3 males
453 and 17 females) was defined as having a BMI of 30.0–49.9 kg/m² and normal fasting plasma
454 glucose, oral glucose tolerance, plasma triglycerides, and IHTG content and normal whole-body
455 insulin sensitivity. MUO (n = 20; 3 males and 17 females) was defined as having a BMI of 30.0–
456 49.9 kg/m², impaired fasting glucose or oral glucose tolerance, high IHTG content (≥5%) and
457 impaired whole-body insulin sensitivity, defined as a GIR/I < 40 (μg/kg FFM/min)/(μU/mL). There
458 were no differences in BMI, body fat%, fat-free mass, or subcutaneous abdominal adipose tissue
459 volume between the MHO and MUO, and these two groups were matched for sex and age.
460 Abdominal subcutaneous adipose tissue was collected from the periumbilical area by aspiration
461 using a 3-mm liposuction cannula (Tulip Medical Products, San Diego, CA) connected to a 60cc
462 syringe. Samples were immediately rinsed in ice-cold saline, flash frozen in liquid nitrogen. RNA
463 extraction and sequencing were completed on 15 MHL, 19 MHO, and 19 MUO as described

464 previously (20). Gene count matrix was acquired from GSE244118 and subsequently normalized
465 using DEseq2.

466

467 *MD lipolysis cohorts.* The study cohort includes 27 white females (aged 54-70 years) and males
468 (aged 50-70 years), who were classified into three groups (21). Lean (n=9; 6 females and 3 males)
469 was defined as having a BMI of 18-25 kg/m², normal fasting glucose (fP-Glucose < 6.1mmol/l),
470 HbA1c (<42 mmol/mol), and fasting insulin (fS-Insulin < 7.0mU/l). Individuals with obesity with
471 insulin resistance (Obese IR) (n=9; 5 females and 4 males) was defined as having a BMI of 30-
472 40 kg/m², fP-Glucose < 7.0 mmol/l, HbA1c (<48mmol/mol), and fS-Insulin (≥9.0 mU/l). Individuals
473 with obesity with type 2 diabetes (Obese T2D) (n=9; 5 females and 4 males) had BMI of 30-40
474 kg/m², and have been diagnosed with T2D less than 6 years. Obese NGT and Obese T2D were
475 matched for age, sex, menopausal status, BMI, and fat mass. Abdominal subcutaneous adipose
476 tissue was collected from the periumbilical area by needle aspiration. RNA extraction and
477 sequencing were completed on 9 Lean, 8 MHO (4 females and 4 males), and 8 MUO (4 females
478 and 4 males) as described previously (21). Gene count matrix was acquired from GSE141432
479 and subsequently normalized using DEseq2.

480

481 *Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy (CALERIE)*
482 *cohorts.* CALERIE cohort includes healthy men (aged 21-50 years) and premenopausal women
483 (aged 21-47 years) without obesity (BMI, 22-27.9 kg/m²) who were enrolled in a randomized,
484 controlled trial that targeted to evaluate the time-course effects of 25% calorie restriction (CR)
485 below the subject's baseline level over a 24 months period. Recruited participants were
486 randomized into either an ad libitum (AL) control group or CR group. RNA-Seq was completed on
487 13 AL participants and 23 CR participants (62). In the AL group, RNAseq was conducted on 11
488 participants at month 12 and 6 participants at month 24. In the CR group, RNA-Seq was
489 conducted on 23 participants at month 12 and 12 participants at month 24. Detailed subject
490 characteristics are provided in Table S1.

491

492 *Diet, Obesity, and Genes (DiOGenes) study cohorts.* DiOGenes cohort includes adults with
493 overweight/obesity as having a BMI of 27-45 kg/m² and aged 18-65 years (63). 220 participants
494 underwent low-calorie-diet (LCD) period for 8 weeks. During the 8-week weight-loss phase,
495 participants received an LCD that provided 3.3 MJ (800 kcal) per day with the use of Modifast
496 products (Nutrition et Santé). Participants were allowed to eat up to 400 g of vegetables, providing
497 a total, including the LCD, of 3.3 to 4.2 MJ (800 to 1000 kcal) per day. Abdominal subcutaneous
498 adipose tissue biopsies were obtained by needle aspiration, about 10 cm from the umbilicus,
499 under local anesthesia after an overnight fast. Samples were obtained at baseline and upon
500 weight loss. RNA extraction and sequencing were completed on samples as described previously
501 (26). Gene count matrix was acquired from GSE1412221 and subsequently normalized using
502 DEseq2.

503

504 *Very-low-calorie diet (VLCD) cohorts.* 10 postmenopausal females with obesity (age: 61±4 years)
505 having a BMI >35 kg/m² underwent VLCD that induced approximately 10% of weight loss (27).
506 The VLCD consisted of a commercially available diet (New Direction Program, Robard Corp.,
507 Mount Laurel, NJ) that provided ~800 kcal per day with an estimated macronutrient energy

508 distribution of 54% protein, 26% carbohydrate, 20% fat (including 4% saturated fat and 200 mg
509 of cholesterol), and 10g of fiber. Baseline abdominal subcutaneous adipose tissue biopsy
510 specimen was taken in the left lower quadrant of the abdomen of each subject, whereas the post
511 weight-loss biopsy specimen was taken in the right lower quadrant abdomen. RNA extraction and
512 sequencing were completed as described previously (27). DESeq2-normalized gene count matrix
513 was acquired from GSE106289.

514

515 **STATISTICS**

516 Pearson's correlation coefficient was used to calculate all correlation analyses. Two-tailed
517 independent Student's t-test was used to compare LCAT cohorts with obesity vs. lean. One-way
518 ANOVA was used to compare MHL vs. MHO vs. MUO and Lean vs. Obese-IR vs. Obese-T2D.
519 Two-way ANOVA linear mixed model was applied to examine the main effects of time, group, and
520 time x group interaction effects from CALERIE cohorts (time, Baseline vs. Year1 vs. Year2; group,
521 AL vs. CR). For significant ANOVA results, post hoc pairwise comparisons were performed using
522 the estimated marginal means with Tukey's adjustment for multiple comparisons. Two-tailed
523 paired Student's T test was used to examine the effect of DIWL in DiOGenes cohorts and women
524 with obesity in Aleman et al., 2017. Statistical computations were performed using R (R, Vienna,
525 Austria). P value < 0.05 was considered statistically significant.

526

527

528 **DATA AND CODE AVAILABILITY**

529 Gene signature matrix and top 6000 HVG list have been uploaded to
530 <https://github.com/KWhytock13/deconvolution-wat>.

531 Code for generating source data and running the deconvolution pipeline is also available at
532 <https://github.com/KWhytock13/deconvolution-wat>.

533

534 **ACKNOWLEDGMENTS**

535 This study was supported by The National Institutes of Health (R01 AG066474, U01 AR071133
536 supplement). Data from the CALERIE analysis was supported by the National Institutes of Health
537 **(R01 AG061378, R33 AG070455)**

538

539 **AUTHOR CONTRIBUTIONS**

540 CA, MMS, LMS, and KW designed the study. All authors contributed to data acquisition, analysis,
541 and interpretation. CA, LMS, and KW drafted the work. All authors have participated in revising
542 the work and approved the final version of the manuscript. We would like to thank Dr. Daniel
543 Belsky, Dr Kim Huffman and Dr Calen Ryan for sharing CALERIE RNA-Seq data for our analyses.

544

545 **COMPETING INTERESTS**

546 The authors declare that they have no competing interests.

547

	AL			CR		
Time point	Baseline (n=14)	Month 12 (n=11)	Month 24 (n=6)	Baseline (n=23)	Month 12 (n=23)	Month 24 (n=12)
Age (y)	38 ± 8	NA	NA	37 ± 7	NA	NA
Sex	8F, 6M	5F, 6M	3F, 3M	18F, 5M	18F, 5M	9F, 3M
BMI (kg/m ²)	25.1 ± 1.4	25.1 ± 1.9	26.0 ± 2.4	25.5 ± 1.6	22.4 ± 1.6 ^{a,b,c,d}	22.6 ± 1.9 ^{a,b,c,d}
Weight (kg)	74.6 ± 9.7	75.3 ± 11.6	78.0 ± 8.0	71.5 ± 9.2	63.0 ± 8.9 ^{a,b,c,d}	63.5 ± 9.1 ^{a,b,c,d}
Δ Fat mass (kg)	NA	0.3 ± 1.7	0.2 ± 1.9	NA	-6.2 ± 2.0 ^{b,c}	-6.5 ± 1.9 ^{b,c}
Δ Fat-free mass (kg)	NA	0.1 ± 0.9	0.9 ± 1.3	NA	-2.0 ± 1.2 ^{b,c}	-1.8 ± 1.1 ^{b,x}

548 **Table S1. CALERIE™ subject characteristics.**

549 Basic subject characteristics from CALERIE™ participants whose ASAT samples were
 550 sequenced and used for deconvolution. a, significantly different against AL-Baseline; b,
 551 significantly different against AL-Month 12; c, significantly different against AL-Month 24. d,
 552 significantly different against CR-Baseline. AL, Ad Libitum; CR, Calorie Restriction, BMI, Body
 553 Mass Index.

554

555

556

	DiOgenes (8-week LCD)	Aleman et al., 2017 (10% Weight loss targeted VLCD)
Age (y)	41 ± 6	61 ± 4
Baseline BMI (kg/m ²)	34.8 ± 4.9	38.8 ± 3.4
Weight loss during intervention (%)	-11.1 ± 2.7	-10.3
Intervention Duration (weeks)	~8	6.6 ± 2.2

557 **Table S2. Subject characteristics of DioGenes and Aleman et al., 2017.**

558

559

560 **FIGURE LEGENDS**

561

562 **Figure 1. Assessment of deconvolution algorithms.**

563 (A) The percentage of samples from the METSIM cohort that are estimated to contain that cell
564 type when predicted with different deconvolution algorithms using log normalized signature matrix
565 from all detected genes. (B) The percentage of samples from the METSIM cohort that are
566 estimated to have >25% of adipocytes predicted with different deconvolution algorithms using log
567 normalized signature matrix from all detected genes. (C) The Pearson's correlation coefficient
568 (PCC) comparing estimated cell proportions from pseudobulk RNA-Seq data against quantified
569 cell proportions from snRNA-Seq for different algorithms for each cell type (D) and the average
570 PCC score across all cell types. (E) The mean absolute deviation (mAD) between estimated cell
571 proportions pseudobulk RNA-Seq data and quantified cell proportions from snRNA-Seq for
572 different algorithms for each cell type (F) and the average mAD score across all cell types. If box
573 is grey the algorithm did not estimate that cell type and PCC therefore cannot be quantified. HVG,
574 Highly variable genes.

575

576 **Figure 2. Correlation between estimated macrophage proportions and BMI or WHR using
577 different gene signatures to subset the signature matrix.**

578 (A) Estimated cell type proportions of each METSIM RNA-Seq samples using different HVG to
579 modify the signature matrix. Algorithm dtangle was used and the data was log normalized. (B) R
580 value and $-\log_{10}(\text{p value})$ for estimated macrophage proportion and WHR for the METSIM RNA-
581 Seq data. (C) Scatterplot showing the estimated macrophage proportion and WHR for the 6000
582 HVG or (D) all genes signature.

583

584 **Figure 3. Estimated ASAT cell type proportions from cross-sectional obesity studies.**

585 (A) Deconvoluted ASAT cell type proportions from lean and obese cohorts in LCAT study (19).
586 Sample size: Normal weight = 35, Obese = 26. (B) Deconvoluted ASAT cell type proportions from
587 cohorts of MHL, MHO, and MUO (20). Post-hoc Tukey HSD was used for cell types with significant
588 ANOVA group differences. Sample size: MHL= 15, MHO = 19, MUO = 19. (C) Deconvoluted
589 ASAT cell type proportions from cohorts of lean, Obese with IR, and Obese with T2D in MD
590 lipolysis cohorts (21). Tukey HSD was used for post hoc analysis of cell types with significant
591 ANOVA group differences. Sample size: Lean = 9, Obese IR = 8, Obese T2D = 8. (D) Number of
592 marker genes for LAM or resident macrophage that are significantly associated with the estimate
593 proportion of macrophages in each study (19-21). LCAT; Leipzig Childhood Adipose Tissue, MHL;
594 Metabolically Healthy Lean, MHO: Metabolically Healthy Obese, MUO; Metabolically Unhealthy
595 Obese, HSD; Honestly Significant Difference, IR; Insulin resistance, T2D; Type 2 Diabetes. LAM;
596 Lipid associated macrophage.

597

598 **Figure 4. Estimated ASAT cell type proportions from longitudinal DIWL studies.**

599 (A) Deconvoluted ASAT cell type proportions from CALERIETM cohorts. Least square means was
600 used for post hoc analysis of macrophage in the CR group. Sample size; AL-Baseline, n=14, AL-
601 Month 12, n=11, AL-Month 24, n=6; CR-Baseline, n=23; CR-Month12, n=23; CR-Month 24, n=12.
602 (B) Correlation between change of fat mass (Δ kg) and change of cell type proportions (Δ %) in
603 CALERIETM participants who completed 12-month intervention. (C) Deconvoluted ASAT cell type

604 proportions from DioGenes cohorts who underwent 8-week low-calorie diet using meal
605 replacement product (26). Sample size = 220. (D) Deconvoluted ASAT cell type proportions from
606 women with obesity who achieved 10% weight loss by very low-calorie diet (27). Sample size =
607 10. (E) Number of marker genes for LAM or resident macrophage that are significantly associated
608 with the estimate proportion of macrophages in each study (26, 27, 29). DIWL, Diet-induced
609 weight loss; AL, Ad Libitum; CR, Calorie Restriction.

610
611

- 612 1. Kershaw EE, and Flier JS. Adipose tissue as an endocrine organ. *The Journal of Clinical*
613 *Endocrinology & Metabolism*. 2004;89(6):2548-56.
- 614 2. Goodpaster BH, and Sparks LM. Metabolic Flexibility in Health and Disease. *Cell Metab*.
615 2017;25(5):1027-36.
- 616 3. Trayhurn P. Endocrine and signalling role of adipose tissue: new perspectives on fat. *Acta*
617 *Physiologica Scandinavica*. 2005;184(4):285-93.
- 618 4. Eto H, Suga H, Matsumoto D, Inoue K, Aoi N, Kato H, et al. Characterization of structure
619 and cellular components of aspirated and excised adipose tissue. *Plastic and*
620 *reconstructive surgery*. 2009;124(4):1087-97.
- 621 5. Corvera S. Cellular Heterogeneity in Adipose Tissues. *Annu Rev Physiol*. 2021;83:257-
622 78.
- 623 6. Frayn KN. Adipose tissue as a buffer for daily lipid flux. *Diabetologia*. 2002;45(9):1201-10.
- 624 7. Goossens GH. The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and
625 Adipose Tissue Function. *Obes Facts*. 2017;10(3):207-15.
- 626 8. Klötting N, Fasshauer M, Dietrich A, Kovacs P, Schön MR, Kern M, et al. Insulin-sensitive
627 obesity. *American Journal of Physiology-Endocrinology and Metabolism*.
628 2010;299(3):E506-E15.
- 629 9. Brotman SM, Oravilaiti A, Rosen JD, Alvarez M, Heinonen S, van der Kolk BW, et al. Cell-
630 Type Composition Affects Adipose Gene Expression Associations With Cardiometabolic
631 Traits. *Diabetes*. 2023;72(11):1707-18.
- 632 10. Schleh MW, Ameka M, Rodriguez A, and Hasty AH. Deficiency of the hemoglobin-
633 haptoglobin receptor, CD163, worsens insulin sensitivity in obese male mice. *bioRxiv*.
634 2024.
- 635 11. Kosteli A, Sugaru E, Haemmerle G, Martin JF, Lei J, Zechner R, and Ferrante AW, Jr.
636 Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue.
637 *J Clin Invest*. 2010;120(10):3466-79.
- 638 12. Aron-Wisnewsky J, Tordjman J, Poitou C, Darakhshan F, Hugol D, Basdevant A, et al.
639 Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous
640 and omental depots and after weight loss. *The Journal of Clinical Endocrinology &*
641 *Metabolism*. 2009;94(11):4619-23.
- 642 13. Whytock KL, Divoux A, Sun Y, Pino MF, Yu G, Jin CA, et al. Aging human abdominal
643 subcutaneous white adipose tissue at single cell resolution. *Aging Cell*. 2024:e14287.
- 644 14. Emont MP, Jacobs C, Essene AL, Pant D, Tenen D, Colletuori G, et al. A single-cell atlas
645 of human and mouse white adipose tissue. *Nature*. 2022;603(7903):926-33.
- 646 15. Massier L, Jalkanen J, Elmastas M, Zhong J, Wang T, Nono Nankam PA, et al. An
647 integrated single cell and spatial transcriptomic map of human white adipose tissue. *Nat*
648 *Commun*. 2023;14(1):1438.
- 649 16. Raulerson CK, Ko A, Kidd JC, Currin KW, Brotman SM, Cannon ME, et al. Adipose Tissue
650 Gene Expression Associations Reveal Hundreds of Candidate Genes for Cardiometabolic
651 Traits. *Am J Hum Genet*. 2019;105(4):773-87.

- 652 17. Lee M-J, Wu Y, and Fried SK. Adipose tissue heterogeneity: implication of depot
653 differences in adipose tissue for obesity complications. *Molecular aspects of medicine*.
654 2013;34(1):1-11.
- 655 18. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, and Ferrante AW. Obesity
656 is associated with macrophage accumulation in adipose tissue. *The Journal of clinical*
657 *investigation*. 2003;112(12):1796-808.
- 658 19. Yang CH, Fagnocchi L, Apostle S, Wegert V, Casani-Galdon S, Landgraf K, et al.
659 Independent phenotypic plasticity axes define distinct obesity sub-types. *Nat Metab*.
660 2022;4(9):1150-65.
- 661 20. Petersen MC, Smith GI, Palacios HH, Farabi SS, Yoshino M, Yoshino J, et al.
662 Cardiometabolic characteristics of people with metabolically healthy and unhealthy
663 obesity. *Cell Metab*. 2024;36(4):745-61 e5.
- 664 21. Fryk E, Olausson J, Mossberg K, Strindberg L, Schmelz M, Brogren H, et al.
665 Hyperinsulinemia and insulin resistance in the obese may develop as part of a
666 homeostatic response to elevated free fatty acids: A mechanistic case-control and a
667 population-based cohort study. *EBioMedicine*. 2021;65:103264.
- 668 22. Crewe C, An YA, and Scherer PE. The ominous triad of adipose tissue dysfunction:
669 inflammation, fibrosis, and impaired angiogenesis. *The Journal of clinical investigation*.
670 2017;127(1):74-82.
- 671 23. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE, et al. Reduced
672 adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage
673 chemotaxis, and inflammation without an angiogenic response. *Diabetes*. 2009;58(3):718-
674 25.
- 675 24. Bluher M. Adipose tissue dysfunction contributes to obesity related metabolic diseases.
676 *Best Pract Res Clin Endocrinol Metab*. 2013;27(2):163-77.
- 677 25. Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC, et al. Effects of
678 Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose
679 Tissue Biology in Humans with Obesity. *Cell Metab*. 2016;23(4):591-601.
- 680 26. Imbert A, Vialaneix N, Marquis J, Vion J, Charpagne A, Metairon S, et al. Network
681 Analyses Reveal Negative Link Between Changes in Adipose Tissue GDF15 and BMI
682 During Dietary-induced Weight Loss. *J Clin Endocrinol Metab*. 2022;107(1):e130-e42.
- 683 27. Aleman JO, Iyengar NM, Walker JM, Milne GL, Da Rosa JC, Liang Y, et al. Effects of
684 Rapid Weight Loss on Systemic and Adipose Tissue Inflammation and Metabolism in
685 Obese Postmenopausal Women. *J Endocr Soc*. 2017;1(6):625-37.
- 686 28. Fritzen AM, Lundsgaard AM, Jordy AB, Poulsen SK, Stender S, Pilegaard H, et al. New
687 Nordic Diet-Induced Weight Loss Is Accompanied by Changes in Metabolism and AMPK
688 Signaling in Adipose Tissue. *J Clin Endocrinol Metab*. 2015;100(9):3509-19.
- 689 29. Rickman AD, Williamson DA, Martin CK, Gilhooly CH, Stein RI, Bales CW, et al. The
690 CALERIE Study: design and methods of an innovative 25% caloric restriction intervention.
691 *Contemp Clin Trials*. 2011;32(6):874-81.
- 692 30. Russo L, and Lumeng CN. Properties and functions of adipose tissue macrophages in
693 obesity. *Immunology*. 2018;155(4):407-17.
- 694 31. Åkra S, Aksnes TA, Flaa A, Eggesbø HB, Opstad TB, Njerve IU, and Seljeflot I. Markers
695 of remodeling in subcutaneous adipose tissue are strongly associated with overweight
696 and insulin sensitivity in healthy non-obese men. *Scientific Reports*. 2020;10(1):14055.
- 697 32. Mozaffarian D, Hao T, Rimm EB, Willett WC, and Hu FB. Changes in diet and lifestyle and
698 long-term weight gain in women and men. *New England journal of medicine*.
699 2011;364(25):2392-404.
- 700 33. Tam CS, Tordjman J, Divoux A, Baur LA, and Clement K. Adipose tissue remodeling in
701 children: the link between collagen deposition and age-related adipocyte growth. *J Clin*
702 *Endocrinol Metab*. 2012;97(4):1320-7.

- 703 34. Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, et al.
704 Dynamics of fat cell turnover in humans. *Nature*. 2008;453(7196):783-7.
- 705 35. Landgraf K, Rockstroh D, Wagner IV, Weise S, Tauscher R, Schwartze JT, et al. Evidence
706 of early alterations in adipose tissue biology and function and its association with obesity-
707 related inflammation and insulin resistance in children. *Diabetes*. 2015;64(4):1249-61.
- 708 36. Ravussin E, and Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat
709 cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes
710 mellitus. *Ann N Y Acad Sci*. 2002;967:363-78.
- 711 37. Cypess AM. Reassessing human adipose tissue. *New England Journal of Medicine*.
712 2022;386(8):768-79.
- 713 38. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease.
714 *N Engl J Med*. 2014;371(12):1131-41.
- 715 39. Nicklas BJ, Ambrosius W, Messier SP, Miller GD, Penninx BW, Loeser RF, et al. Diet-
716 induced weight loss, exercise, and chronic inflammation in older, obese adults: a
717 randomized controlled clinical trial. *Am J Clin Nutr*. 2004;79(4):544-51.
- 718 40. Christiansen T, Paulsen SK, Bruun JM, Pedersen SB, and Richelsen B. Exercise training
719 versus diet-induced weight-loss on metabolic risk factors and inflammatory markers in
720 obese subjects: a 12-week randomized intervention study. *Am J Physiol Endocrinol*
721 *Metab*. 2010;298(4):E824-31.
- 722 41. Meydani SN, Das SK, Pieper CF, Lewis MR, Klein S, Dixit VD, et al. Long-term moderate
723 calorie restriction inhibits inflammation without impairing cell-mediated immunity: a
724 randomized controlled trial in non-obese humans. *Aging (Albany NY)*. 2016;8(7):1416.
- 725 42. Capel F, Klimcakova E, Viguerie N, Roussel B, Vitkova M, Kovacikova M, et al.
726 Macrophages and adipocytes in human obesity: adipose tissue gene expression and
727 insulin sensitivity during calorie restriction and weight stabilization. *Diabetes*.
728 2009;58(7):1558-67.
- 729 43. Asterholm IW, Tao C, Morley TS, Wang QA, Delgado-Lopez F, Wang ZV, and Scherer
730 PE. Adipocyte inflammation is essential for healthy adipose tissue expansion and
731 remodeling. *Cell metabolism*. 2014;20(1):103-18.
- 732 44. Murphy J, Moullec G, and Santosa S. Factors associated with adipocyte size reduction
733 after weight loss interventions for overweight and obesity: a systematic review and meta-
734 regression. *Metabolism*. 2017;67:31-40.
- 735 45. Ejaz A, Mitterberger MC, Lu Z, Mattesich M, Zwierzina ME, Horl S, et al. Weight Loss
736 Upregulates the Small GTPase DIRAS3 in Human White Adipose Progenitor Cells, Which
737 Negatively Regulates Adipogenesis and Activates Autophagy via Akt-mTOR Inhibition.
738 *EBioMedicine*. 2016;6:149-61.
- 739 46. Rossmeislova L, Malisova L, Kracmerova J, Tencerova M, Kovacova Z, Koc M, et al.
740 Weight loss improves the adipogenic capacity of human preadipocytes and modulates
741 their secretory profile. *Diabetes*. 2013;62(6):1990-5.
- 742 47. Lofgren P, Andersson I, Adolfsson B, Leijonhufvud BM, Hertel K, Hoffstedt J, and Arner
743 P. Long-term prospective and controlled studies demonstrate adipose tissue
744 hypercellularity and relative leptin deficiency in the postobese state. *J Clin Endocrinol*
745 *Metab*. 2005;90(11):6207-13.
- 746 48. Prins JB, Walker NI, Winterford CM, and Cameron DP. Human adipocyte apoptosis occurs
747 in malignancy. *Biochemical and biophysical research communications*. 1994;205(1):625-
748 30.
- 749 49. Fischer-Posovszky P, Wang QA, Asterholm IW, Rutkowski JM, and Scherer PE. Targeted
750 deletion of adipocytes by apoptosis leads to adipose tissue recruitment of alternatively
751 activated M2 macrophages. *Endocrinology*. 2011;152(8):3074-81.
- 752 50. Sabina Pfister VK, Enrico Ferrero. granulator: Rapid benchmarking of methods for *in
753 silico* deconvolution of bulk RNA-seq data. 2024.

- 754 51. Monaco G, Lee B, Xu W, Mustafah S, Hwang YY, Carre C, et al. RNA-Seq Signatures
755 Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell
756 Types. *Cell Rep.* 2019;26(6):1627-40 e7.
- 757 52. Gong T, and Szustakowski JD. DeconRNASeq: a statistical framework for deconvolution
758 of heterogeneous tissue samples based on mRNA-Seq data. *Bioinformatics.*
759 2013;29(8):1083-5.
- 760 53. Abbas AR, Wolslegel K, Seshasayee D, Modrusan Z, and Clark HF. Deconvolution of
761 blood microarray data identifies cellular activation patterns in systemic lupus
762 erythematosus. *PLoS One.* 2009;4(7):e6098.
- 763 54. Hunt GJ, Freytag S, Bahlo M, and Gagnon-Bartsch JA. dtangle: accurate and robust cell
764 type deconvolution. *Bioinformatics.* 2019;35(12):2093-9.
- 765 55. Danziger SA, Gibbs DL, Shmulevich I, McConnell M, Trotter MWB, Schmitz F, et al.
766 ADAPTS: Automated deconvolution augmentation of profiles for tissue specific cells.
767 *PLoS One.* 2019;14(11):e0224693.
- 768 56. Altboum Z, Steuerma Y, David E, Barnett-Itzhaki Z, Valadarsky L, Keren-Shaul H, et al.
769 Digital cell quantification identifies global immune cell dynamics during influenza infection.
770 *Mol Syst Biol.* 2014;10(2):720.
- 771 57. Wang X, Park J, Susztak K, Zhang NR, and Li M. Bulk tissue cell type deconvolution with
772 multi-subject single-cell expression reference. *Nat Commun.* 2019;10(1):380.
- 773 58. Racle J, and Gfeller D. EPIC: a tool to estimate the proportions of different cell types from
774 bulk gene expression data. *Bioinformatics for cancer immunotherapy: methods and
775 protocols.* 2020:233-48.
- 776 59. Laakso M, Kuusisto J, Stancakova A, Kuulasmaa T, Pajukanta P, Lusia AJ, et al. The
777 Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular
778 diseases. *J Lipid Res.* 2017;58(3):481-93.
- 779 60. Langfelder P, and Horvath S. WGCNA: an R package for weighted correlation network
780 analysis. *BMC Bioinformatics.* 2008;9:559.
- 781 61. Dalgaard K, Landgraf K, Heyne S, Lempradl A, Longinotto J, Gossens K, et al. Trim28
782 Haploinsufficiency Triggers Bi-stable Epigenetic Obesity. *Cell.* 2016;164(3):353-64.
- 783 62. Ryan CP, Corcoran DL, Banskota N, Eckstein IC, Floratos A, Friedman R, et al. The
784 CALERIE() Genomic Data Resource. *bioRxiv.* 2024.
- 785 63. Larsen TM, Dalskov S-M, van Baak M, Jebb SA, Papadaki A, Pfeiffer AF, et al. Diets with
786 high or low protein content and glycemic index for weight-loss maintenance. *New England
787 Journal of Medicine.* 2010;363(22):2102-13.
- 788
- 789

Fig 1A





Fig 1C




Fig 1D




Fig 1E




Fig 1F




Fig 2A




Fig 2B




Fig 2C




Fig 2D




Fig 3A

LCAT cohorts (0-18 yrs)




Fig 3B

Petersen et al., 2024 (18-35 yrs)




Fig 3C

MD lipolysis cohorts (50-70 yrs)




Fig 3D




Fig 4A




Fig 4B




Fig 4C




Fig 4D





Fig 4E



A






Figure S1. The capability of different algorithms to predict cell types in bulk RNA-Seq data from METSIM and normalized counts from snRNA-Seq.

(A) The percentage of samples from the METSIM cohort that are estimated to contain that cell type when predicted with different deconvolution algorithms using log normalized signature matrix subset to 5000 HVG. (B) The percentage of samples from the METSIM cohort that are estimated to have >25% of adipocytes predicted with different deconvolution algorithms using log normalized signature matrix subset to 5000 HVG.


A



C



D



E




Figure S2. HVG optimization.

(A) Estimated cell type proportions of each METSIM bulk RNA-Seq samples using different HVG to modify the signature matrix. Algorithm dtangle was used and the data was log normalized. R value and $-\log_{10}(p \text{ value})$ for estimated macrophage proportion and BMI for the METSIM bulk RNA-Seq data. Scatterplot showing the estimated macrophage proportion and BMI for the 6000 HVG or all genes signature. (B) Deconvolution result of METSIM bulk RNA-seq using age-group-specific gene signature matrix and 6000 HVG. (C) Bland-Altman plots for estimated proportion of each cell type using Older ($n=10$) vs. young ($n=10$) snRNAseq data. Contrast is Older - Younger. Points above dashed line ($Y=0$) indicates higher estimation of cell proportion when using reference data from Older individuals. (D) Venn diagram of overlapping HVG among integrated 6000 HVG, Old-specific 6000 HVG, and Young-specific 6000 HVG. (E) Scatter plot for each cell type showing correlation between estimated cell proportion in METSIM using integrated 6000 HVG and 'age-neutral' 4762 HVG.